Related Experiment Videos
Endothelin and endothelin receptor antagonism in heart failure
Insights
Endothelin-1 (ET-1) plays a key role in cardiovascular diseases (CVD) and congestive heart failure (CHF). ET-1 receptor antagonists show promise for treating CVD, but long-term survival benefits in CHF require further investigation.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Endothelin (ET)-1 is a potent vasoconstrictor implicated in cardiovascular diseases (CVD) and congestive heart failure (CHF).
- The ET system's role in cardiovascular pathology is increasingly recognized.
- ET-1 exhibits growth-promoting and mitogenic properties relevant to disease progression.
Purpose of the Study:
- To evaluate the therapeutic potential of Endothelin (ET)-1 receptor antagonists in cardiovascular diseases (CVD).
- To assess the clinical efficacy of ET-1 inhibition in patients with congestive heart failure (CHF).
- To determine if ET-1 antagonists offer benefits beyond hemodynamic improvements and impact long-term survival in CHF.
Main Methods:
- Clinical trials involving acute and chronic inhibition of the ET system.
- Administration of oral ET-1 receptor antagonists, such as bosentan.
- Evaluation of hemodynamic effects and long-term survival in patients with CHF.
Main Results:
- Early human trials of ET-1 system inhibition demonstrated promising results.
- Experimental models corroborate the findings from clinical studies.
- Oral compounds like bosentan offer potential as a new therapeutic class for CVD and CHF.
Conclusions:
- ET-1 receptor antagonists represent a novel therapeutic avenue for cardiovascular diseases (CVD).
- Further research is necessary to ascertain the long-term survival benefits of these agents in congestive heart failure (CHF).
- The clinical utility of ET-1 antagonists hinges on demonstrating efficacy beyond immediate hemodynamic changes.
Abstract:
Endothelin (ET)-1 is a potent vasoconstrictor with growth promoting and mitogenic properties associated with various cardiovascular diseases (CVD) and has been found to be an important protagonist in congestive heart failure (CHF). The introduction of ET-1 receptor antagonists into the arena of clinical research has amplified our understanding of the ET system: the first human trials with acute and chronic inhibition of the ET system have shown promising results and confirm the findings from experimental models. The availability of oral compounds such as bosentan has raised the hope that these novel drugs might become a new therapeutic class of agents for the treatment of CVD and, in particular, of CHF. The question, however, remains whether the beneficial effects observed so far in patients with CHF go beyond simple hemodynamic improvements and whether these compounds improve long-term survival in these patients.